EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.

Epizyme, Inc.

400 Technology Square
4th Floor
Cambridge, MA 02139
United States
617-229-5872
http://www.epizyme.com

SettoreHealthcare
SettoreBiotechnology
Impiegati a tempo pieno124

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Robert B. Bazemore Jr.Pres, CEO, Sec. & Director901,93kN/D1968
Mr. Matthew E. RosChief Strategy & Bus. Officer619,31k1,2M1967
Dr. Shefali Agarwal M.D., MPHChief Medical Officer526,76kN/D1974
Dr. H. Robert HorvitzCo-Founder & Chairman of the Scientific Advisory BoardN/DN/DN/D
Dr. Yi ZhangScientific Co-Founder & Member of The Scientific Advisory BoardN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2018 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Epizyme, Inc. al 4 ottobre 2019 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 6; diritti degli azionisti: 7; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.
Usando Yahoo accetti che Yahoo e i suoi partners utilizzino cookies per fini di personalizzazione e altre finalità